BUSINESS

Aculys Pharma Launches Japan PIII for Narcolepsy Drug Candidate

November 11, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Aculys Pharma said on November 8 that it has initiated a domestic PIII study for its histamine H3 receptor antagonist/inverse agonist pitolisant (BF2.649) for the expected indication of narcolepsy. The timing of its submission has not been disclosed. The PIII…

To read the full story

Aculys Pharma’s Pitolisant Nets Positive Data in Japan PIII
October 22, 2024
Aculys Pharma Begins Japan PI for Narcolepsy Drug Candidate
February 7, 2022

BUSINESS

Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
BMS Seeks Japan Approval for Mezigdomide in Multiple Myeloma
June 11, 2026
SanBio Sees Akuugo Expanding to 20-30 Treatment Centers
June 11, 2026
Rakuten Medical to Promote President Maeda to CEO
June 11, 2026
Metagen Starts Global PI/II Trial of Oral FMT Therapy
June 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag

By Hayate Horiguchi

Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…